Adamis Pharmaceuticals (NSDQ:ADMP) has positioned its emergency allergy treatment as a cheaper alternative to Mylan‘s (NSDQ:MYL) EpiPen device. The company has also set out to prove that its epinephrine injector is easy to use, even by people using an auto-injector for the first time.
Data from a human factors study conducted by Adamis were presented this week at a meeting of the American Academy of Allergy, Asthma and Immunology. The study found that participants could learn how to successfully use Adamis’ Symjepi device, which was approved by the FDA in June last year.
The prospective study enrolled 82 participants, including adults, adolescents and caregivers with and without experience using an epinephrine injector. Half of the participants in each group were trained to use Symjepi before using the product for the first time.
Researchers evaluated the participants’ ability to open the device’s case, retrieve the prefilled syringe, remove the needle cap, insert the needle into the thigh and press the plunger until it stopped.
All of the study’s participants successfully opened the case, retrieved the syringe and removed the needle cap, while 93% of them correctly inserted the needle into their thigh and 99% of them pushed the plunger until it stopped, Adamis reported.
“Human factor studies are important to support the safe and effective use of epinephrine devices used in the treatment of anaphylaxis. This prospective human factor study for this epinephrine device supports the ease and correct use of Symjepi for the acute treatment of anaphylaxis,” Adamis CEO Ronald Moss said in prepared remarks. “Symjepi is a newly approved epinephrine syringe for the treatment of anaphylaxis and should provide a good cost-effective user-friendly alternative to current auto-injectors.”